Crestone Pharma

Coming – November 4

A Transformative Opportunity in Parkinson’s Disease and Autism

Date and Time

November 4

–

12:00 PM ET / 9:00 AM PT

Details will be provided upon RSVP approval

About this Event

Autism and Parkinson’s Disease (PD) impact millions of people, and their effects can be devastating. Recently it was discovered that gastrointestinal symptoms are early warning signs of Parkinson’s Disease and research indicates that alterations in the gut microbiome can have a significant impact on both conditions.

Crestone Pharmaceutical is a clinical stage biotech company focused on developing highly targeted small molecule antibiotics that have the potential to reduce damage early in the development of Parkinson’s disease before neurons that are responsive to dopamine are permanently lost.

Crestone is ready to begin a Phase 2 proof-of-concept trial for PD with CRS3123, an antibiotic with a narrow-spectrum antibacterial mechanism. This allows it to selectively eliminate key gut bacteria responsible for producing p-cresol, a toxic metabolite strongly implicated in disrupting dopamine metabolism in PD. By lowering systemic p-cresol levels, CRS3123 may prevent or slow dopaminergic neuron loss, offering a true disease-modifying intervention for early-stage PD.

They are also studying if this same molecule has beneficial effects in treating Autism, an increasingly prevalent condition with no FDA-approved treatments for core symptoms.

Register today to join our online event with Crestone CEO, Nebojsa Janjic, Ph.D, to hear more about the company’s progress and the impact their scientific advancements can have on these devastating diseases.

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.